The company has previously posted that licensing deals are being discussed. The PR from 2 months ago that used the Bristol deal as a template for what the company wants to do with dcell, timed with the onboarding of the CFO suggests that discussions with Big Pharma are happening also. Your negative opinion in the face of contrary evidence both direct and circumstantial is the only fantasy out there.